Headlines about STERIS (NYSE:STE) have been trending somewhat positive recently, according to Accern. The research group rates the sentiment of press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. STERIS earned a media sentiment score of 0.11 on Accern’s scale. Accern also gave news headlines about the medical equipment provider an impact score of 46.2011605984038 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
Here are some of the headlines that may have impacted Accern’s rankings:
- Endoscopic Reprocessors Market 2018 Share, Trends, Segmentation and Forecast to 2025 (digitaljournal.com)
- Head-To-Head Contrast: Intuitive Surgical (ISRG) & STERIS (STE) (americanbankingnews.com)
- Medical Instruments Disinfections Market is Forecast to Cross US$ 5.0 Billion By 2024 (marketwatch.com)
- Global Sterilization Equipment Market Growth Opportunities: Matachana Group, STERIS Corporation, Belimed AG (marketwatch.com)
- Michael B. Wood Sells 3,800 Shares of STERIS (STE) Stock (americanbankingnews.com)
STE has been the subject of several recent analyst reports. Zacks Investment Research downgraded shares of STERIS from a “buy” rating to a “hold” rating in a research note on Wednesday, March 28th. Northcoast Research set a $102.00 price objective on shares of STERIS and gave the stock a “buy” rating in a research note on Thursday, February 8th. Finally, KeyCorp reiterated a “buy” rating and set a $103.00 price objective on shares of STERIS in a research note on Thursday, February 8th. Three analysts have rated the stock with a hold rating and four have issued a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $86.80.
Shares of NYSE:STE traded down $0.80 on Friday, hitting $103.69. 249,445 shares of the company were exchanged, compared to its average volume of 441,831. STERIS has a 1-year low of $76.47 and a 1-year high of $105.39. The company has a current ratio of 2.48, a quick ratio of 1.97 and a debt-to-equity ratio of 0.41. The company has a market capitalization of $8.87 billion, a P/E ratio of 24.99 and a beta of 1.12.
STERIS (NYSE:STE) last posted its quarterly earnings data on Wednesday, May 9th. The medical equipment provider reported $1.24 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.22 by $0.02. STERIS had a net margin of 11.10% and a return on equity of 11.55%. The business had revenue of $716.00 million during the quarter, compared to the consensus estimate of $703.37 million. During the same period in the previous year, the firm posted $1.11 earnings per share. The business’s revenue for the quarter was up 5.1% compared to the same quarter last year. equities analysts forecast that STERIS will post 4.71 EPS for the current year.
The business also recently disclosed a quarterly dividend, which will be paid on Thursday, June 28th. Stockholders of record on Friday, June 8th will be paid a dividend of $0.31 per share. The ex-dividend date is Thursday, June 7th. This represents a $1.24 annualized dividend and a dividend yield of 1.20%. STERIS’s payout ratio is currently 29.88%.
In related news, Director Cynthia L. Feldmann sold 3,218 shares of the firm’s stock in a transaction on Monday, February 26th. The shares were sold at an average price of $91.35, for a total transaction of $293,964.30. Following the completion of the transaction, the director now owns 11,214 shares of the company’s stock, valued at $1,024,398.90. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Richard Martin Steeves sold 58,953 shares of the firm’s stock in a transaction on Monday, March 5th. The stock was sold at an average price of $91.00, for a total transaction of $5,364,723.00. Following the transaction, the director now directly owns 9,362 shares of the company’s stock, valued at approximately $851,942. The disclosure for this sale can be found here. Insiders have sold 99,407 shares of company stock valued at $9,344,293 over the last quarter. Insiders own 2.55% of the company’s stock.
STERIS Company Profile
STERIS plc develops, manufactures, and markets infection prevention, contamination control, microbial reduction, and surgical and gastrointestinal support products and services for healthcare, pharmaceutical, scientific, research, industrial, and governmental customers worldwide. The company's Healthcare Products segment offers steam, vaporized hydrogen peroxide, and ethylene oxide sterilizers, as well as liquid chemical sterilant processing systems; automated washer/disinfector systems; general and specialty surgical tables, surgical and examination lights, equipment management systems, operating room storage cabinets, warming cabinets, scrub sinks, and other accessories; and gastrointestinal devices and accessories.
Receive News & Ratings for STERIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STERIS and related companies with MarketBeat.com's FREE daily email newsletter.